Children of HIV positive mothers: Pediatric care and perspectives of development;Kinder HIV-positiver mütter: Kinderärztliche betreuung und entwicklungsperspektiven

Gynakologe

Volumn 38, Issue 8, 2005, Pages 701-707

  Niehues, T ^a   Friebe Hoffmann, U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Child age; Highly active antiretroviral therapy; HIV infection; Pregnancy; Prophylaxis of transmission

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

GYNECOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; MEDICAL SPECIALIST; PATIENT CARE; PEDIATRICIAN; PERINATAL INFECTION; PSYCHOLOGIST; PSYCHOSOCIAL CARE; REVIEW; SOCIAL WORKER; TEAMWORK; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 24344465872     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00129-005-1721-1     Document Type: Review

References (29)

1. Aboulker JP, Babiker A, Chaix ML et al.; Paediatric European Network for Treatment of AIDS (2004) Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18: 237-245
2. Brambilla P, Bricalli D, Sala N et al. (2001) Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 15: 2415-2422
3. Buseyne F, Blanche S, Schmitt D et al. (1993) Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children. J Immunol 150: 3569-3581
4. Church JA, Hughes M, Chen J et al; Pediatric AIDS Clinical Trials Group P1005 Study Team (2004) Long-term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 23: 713-718
5. Dunn DT, Brandt CD, Krivine A et al. (1995) The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 9: F7-11
6. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group (2003) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362: 1605-1611
7. Engelhorn C, Hoffmann F, Kurowski M et al. (2004) Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. AIDS 18: 1473-1475
8. Englund JA, Raskino C, Vavro C et al.; Pediatric AIDS Clinical Trials Group Protocol 152 Team (2004) Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J 23: 15-22
9. Fraaij PL, Neubert J, Bergshoeff A et al. (2004) Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 9: 297-299
10. Galli L, de Martino M, Tovo PA et al. (1995) Onset of clinical signs in children with HIV-1 perinatal infection. Italian Register for HIV Infection in Children. AIDS 9: 455-461
11. Gibb DM, Duong T, Leclezio VA et al.; Collaborative HIV Paediatric Study Steering Committee (2004) Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 23:446-450
12. Gotch F, Hardy G (2000) The immune system: our best antiretroviral. Curr Opin Infect Dis 13: 13-17
13. Grosch-Wörner I, Schäfer A, Obladen M et al. (2000) An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 4: 2903-2911
14. Hazra R, Balis FM, Tullio AN et al. (2004) Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 48: 124-129
15. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T (2002) Marked dyslipidemia in HIV-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 110: e56
16. Luzuriaga K, McManus M, Mofenson L et al. (2004) PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 350: 2471-2480
17. McComsey G, Bhumbra N, Ma JF et al. (2003) Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 111: e275-281
18. Mora S, Zamproni I, Beccio S et al. (2004) Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 89: 24-28
19. Nachman SA, Stanley K, Yogev R et al. (2000) Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. JAMA 283: 492-498
20. Niehues T, Wintergerst U, Funk M, Notheis G, für die Konsensusgruppe der Pädiatrischen Arbeitsgemeinschaft AIDS (PAAD) (2001) Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern - Vollständig überarbeitetes und aktualisiertes Konsensus-Statement der PAAD und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI). Monatsschr Kinderheilkd 149: 1372-1382
21. Paediatric European Network for Treatment of AIDS (PENTA) (2002) Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359: 733-740
22. Persaud D, Siberry GK, Ahonkhai A et al. (2004) Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 78: 968-979
23. Saez-Llorens X, Nelson RR Emmanuel P et al. (2001) A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated HIV type 1-infected children. The CNAA3006 Study Team. Pediatrics 107: E4
24. Saez-Llorens X, Violari A, Deetz CO et al. (2003) Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 22: 216-224
25. Van Dyke RB, Lee S, Johnson GM et al.; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team (2002) Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 109: e61
26. van Rossum AM, Fraaij PL, de Groot R (2002) Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2: 93-102
27. Verweel G, Sharland M, Lyall H et al. (2003) Nevirapine use in HIV-1-infected children. AIDS 17: 1639-1647
28. Wang LH, Wiznia AA, Rathore MH et al. (2004) Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 48: 183-191
29. Working Group on Antiretroviral Therapy and Medical Management of HIV Infected Children, National Pediatric and Family Resource Center, Health Resources and Services Administration and National Institutes of Health (2004) Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://www.aidsinfo.nih.gov/guidelines/